Skip to main content

Virus-free Recombinant Polio Vaccine

Award type :
Product Development Award
Product type :
Vaccines
Award year :
2021
Project start date :
07 / 07 / 2021
Project end date :
12 / 30 / 2022
Project duration (months) :
11
Development stage :
Preclinical
Target disease :
Polio
Region served :
World
Recipient organization / Country of funding recipient organization :
Yonsei University / Republic of Korea
Collaborator(s) / Country :
LG Chem / Republic of Korea
Funding amount(KRW) :
500,000,000

Yonsei University is collaborating with LG Chem for the validation of a low-cost, virus-free vaccine platform with the development of a cell-culture-independent, genome-free polio vaccine produced in a bacterial host utilizing RNA as chaperone. The development of an injectable polio vaccine prepared without recourse to growing wild polio virus is not only safer but can also be easily manufactured in response to an urgent need for vaccines in the context of possible post-eradication outbreaks. The virus-free platform using bacterial host production may also be applied to other diseases.